Page 95 - e-CPG-SLE-8_5_24
P. 95
Management of Systemic Lupus Erythematosus
OR odds ratio
PE plasma exchange
PO per os (by oral)
PGA Physician Global Assessment
QID quarter in die (four times a day)
RBC red blood cell
RNA ribonucleic acid
RC review committee
RCT randomised controlled trial
RP renal profile
RR risk ratio
SARS-CoV-2 Severe Acute Respiratory Syndrome Coronavirus 2
SDI SLICC/ACR Damage Index
SF-36 36-item Short Form Health Survey
SIR standardised incidence ratio
SLAM-R Systemic Lupus Activity Measure-Revised
SELENA-SLEDAI Safety of Estrogens in Lupus Erythematosus: National Assessment
- Systemic Lupus Erythematosus Disease Activity Index
SLE systemic lupus erythematosus
SLEDAI Systemic Lupus Erythematosus Disease Activity Index
SLEDAI-2K Systemic Lupus Erythematosus Disease Activity Index 2000
SLEPDAI Systemic Lupus Erythematosus Pregnancy Disease Activity Index
SLICC Systemic Lupus International Collaborating Clinics
SPF sun protection factor
SRI SLE Responder Index
TDM therapeutic drug monitoring
TDS ter die sumendum (three times a day)
TTP thrombotic thrombocytopenic purpura
TULIP Treatment of Uncontrolled Lupus via the Interferon Pathway
U.S. United States
UFEME urine full examination and microscopic examination
UPCR urine protein/creatinine ratio
US ultrasound
USPSTF U.S. Preventive Services Task Force
VAS Visual Analogue Scale
WBC white blood cell
WHO World Health Organization
78